Literature DB >> 22103978

The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China.

Lei Chen1, Yan-Ping Mao, Fang-Yun Xie, Li-Zhi Liu, Ying Sun, Li Tian, Ling-Long Tang, Ai-Hua Lin, Li Li, Jun Ma.   

Abstract

PURPOSE: To evaluate the 7th edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) staging system for nasopharyngeal carcinoma (NPC) in patients treated with intensity-modulated radiotherapy. METHODS AND MATERIALS: We performed a retrospective data review from 512 patients with biopsy-proven, nonmetastatic NPC in our cancer center (South China) between January 2003 and December 2006.
RESULTS: The local relapse-free survival rates (LRFS) and disease failure-free survival rates (DFS) in the 6th edition system T1 and T2a stages were not significantly different (P=0.629 and P=0.820), while the LRFS and DFS of T1 and T2 using the 7th edition system were significantly different (P=0.019 and P=0.009). The LRFS and DFS between T2 and T3 in the 7th edition systems were lack of significance (P=0.874 and P=0.589). The total difference in distant metastasis-free survival rate and DFS between N0 and N3 was slightly larger using the 7th edition system than the 6th edition. The nodal dimension of a cervical lymph node was not a significant prognostic factor.
CONCLUSIONS: We observed a better segregation of survival curves by using the 7th edition system. It seems reasonable to downstage T3 as T2 and reject nodal greatest dimension from the N-staging system in the future revised edition.
Copyright © 2011. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22103978     DOI: 10.1016/j.radonc.2011.10.009

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  71 in total

1.  Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.

Authors:  Ting Jin; Xiao-Zhong Chen; Jian-Jiang Liu
Journal:  Oncol Lett       Date:  2015-06-10       Impact factor: 2.967

2.  Serologic biomarkers of Epstein-Barr virus correlate with TNM classification according to the seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma.

Authors:  Peng Sun; Cui Chen; Yi-Kan Cheng; Zhi-Jian Zeng; Xin-Lin Chen; Li-Zhi Liu; Mo-Fa Gu
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-11-09       Impact factor: 2.503

3.  Prognostic value of 18F-fluorodeoxyglucose PET parameters and inflammation in patients with nasopharyngeal carcinoma.

Authors:  Liting Zhong; Chunming Li; Yunyan Ren; Dehua Wu
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

4.  Diffusion-weighted imaging to differentiate metastatic from non-metastatic retropharyngeal lymph nodes in nasopharyngeal carcinoma.

Authors:  H Li; X-W Liu; Z-J Geng; D-L Wang; C-M Xie
Journal:  Dentomaxillofac Radiol       Date:  2014-11-28       Impact factor: 2.419

5.  Magnetic Resonance Imaging Volumetry of Primary Nasopharyngeal Cancer in Patients Treated with Induction Gemcitabine and Cisplatin Followed by Concurrent Cisplatin and Volumetric Modulated Arc Therapy.

Authors:  Joshua Giambattista; Nevin McVicar; Sarah Hamilton; Montgomery Martin; Benjamin Maas; Cheryl Ho; Jonn Wu; Eric Tran; John Hay; Eric Berthelet
Journal:  Cureus       Date:  2018-09-13

6.  The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients.

Authors:  Rou Jiang; Xiong Zou; Wen Hu; Yu-Ying Fan; Yue Yan; Meng-Xia Zhang; Rui You; Rui Sun; Dong-Hua Luo; Qiu-Yan Chen; Pei-Yu Huang; Yi-Jun Hua; Ling Guo; Ming-Yuan Chen
Journal:  Tumour Biol       Date:  2015-05-06

7.  The value of the Prognostic Nutritional Index (PNI) in predicting outcomes and guiding the treatment strategy of nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy (IMRT) with or without chemotherapy.

Authors:  Jingjing Miao; Weiwei Xiao; Lin Wang; Fei Han; Haijun Wu; Xiaowu Deng; Xiang Guo; Chong Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-28       Impact factor: 4.553

8.  Usefulness of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography combined with the platelet-lymphocyte ratio in predicting the prognosis of nasopharyngeal carcinoma.

Authors:  Wei Jun Xian; Yan Lin Feng; Ying Wang; Ming Yang; Sheng Nan Lu
Journal:  Br J Radiol       Date:  2021-11-23       Impact factor: 3.039

9.  Accuracy of a Staging System for Prognosis of 5-Year Survival of Patients With Nasopharyngeal Carcinoma Who Underwent Chemoradiotherapy.

Authors:  Chung-I Huang; Li-Fu Chen; Shih-Lun Chang; Hung-Chang Wu; Wei-Chen Ting; Ching-Chieh Yang
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-11-01       Impact factor: 6.223

10.  Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma?

Authors:  Yan He; Tao Guo; Jingjing Wang; Yu Sun; Hui Guan; Shaoyong Wu; Xingchen Peng
Journal:  Ann Transl Med       Date:  2019-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.